Filing

Amylyx Pharmaceuticals, Inc. Filed 2023-04-26 Acc 0000899243-23-011780

Documents 1

2023-04-27 ARS Annual Report to Security Holders
2023-04-27 DEFA14A Proxy Materials
2023-04-27 DEF 14A Proxy Statement
2023-04-26 4/A Chief Financial Officer acquired 19,482 shares (conversion)
2023-04-26 3/A 3/A
2023-04-19 4 Chief Medical Officer sold 49,579 shares at an average $30.54 ($1,513,942)
2022-03-17 3/A 3/A

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

Loading xslF345X02/doc3a.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…